Noah Berkowitz Sells 6,435 Shares of Arvinas (NASDAQ:ARVN) Stock

Arvinas, Inc. (NASDAQ:ARVN) insider Noah Berkowitz sold 6,435 shares of the firm’s stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $11.10, for a total value of $71,428.50. Following the sale, the insider directly owned 202,503 shares in the company, valued at approximately $2,247,783.30. This represents a 3.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Noah Berkowitz also recently made the following trade(s):

• On Friday, February 13th, Noah Berkowitz sold 5,685 shares of Arvinas stock. The shares were sold at an average price of $11.89, for a total value of $67,594.65.

Arvinas Stock Performance

NASDAQ ARVN traded up $0.28 during trading hours on Thursday, reaching $11.17. 1,230,582 shares of the company’s stock were exchanged, compared to its average volume of 907,784. The company has a market capitalization of $714.43 million, a price-to-earnings ratio of -8.73 and a beta of 1.87. The company’s 50-day moving average is $12.72 and its two-hundred day moving average is $11.13. Arvinas, Inc. has a one year low of $5.90 and a one year high of $14.51.

Arvinas (NASDAQ:ARVN) last announced its earnings results on Tuesday, February 24th. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.55). The company had revenue of $9.50 million for the quarter, compared to analyst estimates of $37.26 million. Arvinas had a negative return on equity of 14.25% and a negative net margin of 30.77%.The business’s quarterly revenue was down 84.0% on a year-over-year basis. During the same quarter last year, the business posted ($0.63) earnings per share. Research analysts predict that Arvinas, Inc. will post -3.81 earnings per share for the current fiscal year.

Arvinas News Summary

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: Positive Phase 1 data for ARV-102 showed >50% LRRK2 degradation in CSF after 28 days and reductions in endolysosomal and neuroinflammatory biomarkers—data that de‑risks the Parkinson’s program and increases the drug’s clinical value. Arvinas Announces Positive Phase 1 Data for ARV-102
• Positive Sentiment: Citigroup raised its price target from $18 to $21 and initiated/maintained a Buy rating—an analyst upgrade that implies a large upside and can attract momentum investors. Benzinga
• Positive Sentiment: BTIG bumped its target from $14 to $16 and keeps a Buy rating, providing additional brokerage support for the shares and reinforcing the sentiment shift after the clinical news. Benzinga
• Neutral Sentiment: Short-interest reports for mid‑March show anomalous zero/NaN values and a 0.0 days-to-cover figure—data appears unreliable or miscoded and currently offers no clear sign of increased short pressure. Investors should watch for corrected filings for a clearer picture. TipRanks / Short Interest Note

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Citigroup upped their target price on shares of Arvinas from $18.00 to $21.00 and gave the stock a “buy” rating in a research note on Thursday. Barclays lifted their price target on Arvinas from $16.00 to $18.00 and gave the company an “overweight” rating in a research note on Wednesday, December 17th. Truist Financial set a $10.00 price target on Arvinas in a report on Wednesday. Wall Street Zen cut Arvinas from a “hold” rating to a “sell” rating in a research report on Monday, March 2nd. Finally, Piper Sandler reiterated an “overweight” rating and set a $20.00 price objective (up from $16.00) on shares of Arvinas in a report on Wednesday, February 25th. Ten research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $13.88.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. ProShare Advisors LLC increased its stake in Arvinas by 7.2% in the 4th quarter. ProShare Advisors LLC now owns 14,827 shares of the company’s stock valued at $176,000 after buying an additional 993 shares during the last quarter. Intech Investment Management LLC boosted its stake in shares of Arvinas by 3.6% during the 3rd quarter. Intech Investment Management LLC now owns 32,653 shares of the company’s stock worth $278,000 after buying an additional 1,125 shares during the last quarter. MetLife Investment Management LLC boosted its stake in shares of Arvinas by 4.3% during the 4th quarter. MetLife Investment Management LLC now owns 33,810 shares of the company’s stock worth $401,000 after buying an additional 1,381 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Arvinas by 5.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,636 shares of the company’s stock valued at $271,000 after acquiring an additional 2,122 shares in the last quarter. Finally, Oxford Asset Management LLP increased its position in shares of Arvinas by 15.5% in the second quarter. Oxford Asset Management LLP now owns 16,705 shares of the company’s stock valued at $123,000 after acquiring an additional 2,242 shares during the last quarter. Institutional investors and hedge funds own 95.19% of the company’s stock.

About Arvinas

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.